Drug Profile
VM 201
Latest Information Update: 19 Jun 2001
Price :
$50
*
At a glance
- Originator Columbia University
- Class Anticoagulants; Antithrombotics; Blood coagulation factors
- Mechanism of Action Factor IXa inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Blood coagulation disorders; Stroke; Thrombosis
Most Recent Events
- 19 Jun 2001 Discontinued - Preclinical for Coagulation disorders in USA (IV)
- 19 Jun 2001 Discontinued - Preclinical for Stroke in USA (IV)
- 19 Jun 2001 Discontinued - Preclinical for Thrombosis in USA (IV)